Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications
Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors…